SN50 attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation

[1]  Yahui Wang,et al.  Abstract. Aim: Hypercoagulation and fibrinolysis inhibition in the alveolar cavity are important characteristics in acute respiratory distress syndrome (ARDS). Alveolar epithelial cells type II (AEC II) have been confirmed to have significant role in regulating alveolar hypercoagulation and fibrinol , 2019 .

[2]  Yahui Wang,et al.  NF-κB p65 Knock-down inhibits TF, PAI-1 and promotes activated protein C production in lipopolysaccharide-stimulated alveolar epithelial cells type II , 2018, Experimental lung research.

[3]  Roberto Fumagalli,et al.  Definition and epidemiology of acute respiratory distress syndrome. , 2017, Annals of translational medicine.

[4]  Arthur S Slutsky,et al.  GOLDEN anniversary of the acute respiratory distress syndrome: still much work to do! , 2017, Current opinion in critical care.

[5]  D. Baltimore,et al.  30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology , 2017, Cell.

[6]  V. Janout,et al.  Past and Present ARDS Mortality Rates: A Systematic Review , 2017, Respiratory Care.

[7]  I. Jaunalksne,et al.  Activation of Coagulation and Fibrinolysis in Acute Respiratory Distress Syndrome: A Prospective Pilot Study , 2016, Front. Med..

[8]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[9]  M. Griffiths,et al.  Acute respiratory distress syndrome. , 2016, Clinical medicine.

[10]  V. Londhe,et al.  Alveolar NF-κB signaling regulates endotoxin-induced lung inflammation , 2015, Experimental lung research.

[11]  C. Chiang,et al.  Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. , 2014, Translational research : the journal of laboratory and clinical medicine.

[12]  Xiao-Dong Yang,et al.  SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901 , 2013, Archives of medical science : AMS.

[13]  T. van der Poll,et al.  Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome , 2013, Journal of thrombosis and haemostasis : JTH.

[14]  Z. Qin,et al.  Therapeutic effect of SN50, an inhibitor of nuclear factor-κB, in treatment of TBI in mice , 2013, Neurological Sciences.

[15]  D. Lawrence,et al.  PAI‐1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury , 2012, The Journal of pathology.

[16]  S. Ghosh,et al.  Celebrating 25 years of NF‐κB research , 2012, Immunological reviews.

[17]  G. Ghosh,et al.  NF‐κB regulation: lessons from structures , 2012, Immunological reviews.

[18]  S. Powers,et al.  Nuclear factor-&kgr;B signaling contributes to mechanical ventilation-induced diaphragm weakness* , 2012, Critical care medicine.

[19]  I. Verma,et al.  IKK biology , 2012, Immunological reviews.

[20]  F. Fazal,et al.  Blocking NF-κB: an inflammatory issue. , 2011, Proceedings of the American Thoracic Society.

[21]  E. Hod,et al.  Imaging Pulmonary NF-kappaB Activation and Therapeutic Effects of MLN120B and TDZD-8 , 2011, PloS one.

[22]  J. Bastarache,et al.  Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. , 2011, Current pharmaceutical biotechnology.

[23]  M. Matthay,et al.  Acute lung injury: epidemiology, pathogenesis, and treatment. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[24]  H. Redmond,et al.  NF-kappaB and p38 MAPK inhibition improve survival in endotoxin shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy. , 2009, The Journal of surgical research.

[25]  J. Pearl,et al.  Modulation of nuclear factor-kappaB improves cardiac dysfunction associated with cardiopulmonary bypass and deep hypothermic circulatory arrest* , 2009, Critical care medicine.

[26]  L. DelGiudice,et al.  The role of tissue factor and tissue factor pathway inhibitor in health and disease states. , 2009, Journal of veterinary emergency and critical care.

[27]  A. Malik,et al.  NF-κB activation as a pathological mechanism of septic shock and inflammation , 2006 .

[28]  K. Flanders,et al.  Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. , 2005, The American journal of pathology.

[29]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[30]  T. Torgerson,et al.  Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence (*) , 1995, The Journal of Biological Chemistry.